Splenic rupture following lenograstim in post-autologous stem cell transplantation treated with emergency open splenectomy: a case report and literature review.

Abstract

Granulocyte-colony stimulating factors (G-CSFs) are the cornerstone of peripheral blood stem cell mobilization and apheresis. However, splenic rupture following G-CSF treatment represents a serious and potentially fatal adverse event. Here, we report the case of a patient in their late 50s with severe pancytopenia post-autologous stem cell transplantation reinfusion suffering from splenic rupture after treatment with lenograstim. We also reviewed the literature describing cases of splenic rupture during G-CSF administration.

• Authors: Uros Markovic, Cristina Colarossi, Antonio Iuppa, Paola Scire, Ausilia Gorgone, Federica Galbo, Gabriella Amato, Gaetano Moschetti
• Journal: The Journal of international medical research (J Int Med Res) Vol. 50 Issue 5 Pg. 3000605221095504 (May 2022) ISSN: 1473-2300 [Electronic] England
• PMID: 35638556 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Granulocyte Colony-Stimulating Factor
• Lenograstim

Topics

• Granulocyte Colony-Stimulating Factor (adverse effects, therapeutic use)
• Hematopoietic Stem Cell Mobilization (adverse effects)
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Humans
• Lenograstim
• Splenectomy
• Splenic Rupture (etiology, surgery)
• Transplantation, Autologous (adverse effects)